SLC25A51 decouples the mitochondrial NAD+/NADH ratio to control proliferation of AML cells
Copyright © 2024 Elsevier Inc. All rights reserved..
SLC25A51 selectively imports oxidized NAD+ into the mitochondrial matrix and is required for sustaining cell respiration. We observed elevated expression of SLC25A51 that correlated with poorer outcomes in patients with acute myeloid leukemia (AML), and we sought to determine the role SLC25A51 may serve in this disease. We found that lowering SLC25A51 levels led to increased apoptosis and prolonged survival in orthotopic xenograft models. Metabolic flux analyses indicated that depletion of SLC25A51 shunted flux away from mitochondrial oxidative pathways, notably without increased glycolytic flux. Depletion of SLC25A51 combined with 5-azacytidine treatment limits expansion of AML cells in vivo. Together, the data indicate that AML cells upregulate SLC25A51 to decouple mitochondrial NAD+/NADH for a proliferative advantage by supporting oxidative reactions from a variety of fuels. Thus, SLC25A51 represents a critical regulator that can be exploited by cancer cells and may be a vulnerability for refractory AML.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Cell metabolism - 36(2024), 4 vom: 02. Apr., Seite 808-821.e6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lu, Mu-Jie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0U46U6E8UK |
|---|
| Anmerkungen: |
Date Completed 05.04.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cmet.2024.01.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36844841X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36844841X | ||
| 003 | DE-627 | ||
| 005 | 20240409232439.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240215s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmet.2024.01.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM36844841X | ||
| 035 | |a (NLM)38354740 | ||
| 035 | |a (PII)S1550-4131(24)00013-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lu, Mu-Jie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SLC25A51 decouples the mitochondrial NAD+/NADH ratio to control proliferation of AML cells |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a SLC25A51 selectively imports oxidized NAD+ into the mitochondrial matrix and is required for sustaining cell respiration. We observed elevated expression of SLC25A51 that correlated with poorer outcomes in patients with acute myeloid leukemia (AML), and we sought to determine the role SLC25A51 may serve in this disease. We found that lowering SLC25A51 levels led to increased apoptosis and prolonged survival in orthotopic xenograft models. Metabolic flux analyses indicated that depletion of SLC25A51 shunted flux away from mitochondrial oxidative pathways, notably without increased glycolytic flux. Depletion of SLC25A51 combined with 5-azacytidine treatment limits expansion of AML cells in vivo. Together, the data indicate that AML cells upregulate SLC25A51 to decouple mitochondrial NAD+/NADH for a proliferative advantage by supporting oxidative reactions from a variety of fuels. Thus, SLC25A51 represents a critical regulator that can be exploited by cancer cells and may be a vulnerability for refractory AML | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AML | |
| 650 | 4 | |a MCART1 | |
| 650 | 4 | |a SLC25A51 | |
| 650 | 4 | |a glutamine utilization | |
| 650 | 4 | |a oxidative mitochondria | |
| 650 | 4 | |a tumor metabolism | |
| 650 | 7 | |a NAD |2 NLM | |
| 650 | 7 | |a 0U46U6E8UK |2 NLM | |
| 650 | 7 | |a SLC25A51 protein, human |2 NLM | |
| 700 | 1 | |a Busquets, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Impedovo, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Crystal N |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Hsin-Ru |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Yu-Tai |e verfasserin |4 aut | |
| 700 | 1 | |a Matsui, William |e verfasserin |4 aut | |
| 700 | 1 | |a Tiziani, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Cambronne, Xiaolu A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell metabolism |d 2005 |g 36(2024), 4 vom: 02. Apr., Seite 808-821.e6 |w (DE-627)NLM156885433 |x 1932-7420 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2024 |g number:4 |g day:02 |g month:04 |g pages:808-821.e6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmet.2024.01.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2024 |e 4 |b 02 |c 04 |h 808-821.e6 | ||